Summary

Japan Gynecology Drugs Market was valued at USD 229.67 Million in 2024 and is expected to reach USD 342.79 Million by 2030 with a CAGR of 6.88% during the forecast period. The Japan gynecology drugs market is primarily driven by the increasing prevalence of gynecological disorders, such as endometriosis, polycystic ovary syndrome (PCOS), and uterine fibroids, which are becoming more commonly diagnosed due to heightened awareness and better diagnostic tools. Aging demographics also play a role, as conditions like menopause and related symptoms require targeted treatments. Advances in drug development, including hormonal therapies and non-hormonal alternatives, are enhancing treatment options and efficacy. Growing emphasis on women’s health and well-being, supported by government health initiatives and educational programs, contributes to the rising demand for gynecological medications. The expansion of personalized medicine and the introduction of innovative drug delivery systems further fuel market growth by offering tailored and effective solutions for individual patient needs.
Key Market Drivers
Increasing Prevalence of Gynecological Disorders
The rising prevalence of gynecological disorders is a major driver of the Japan gynecology drugs market, reflecting a significant shift in healthcare demands and pharmaceutical innovation. Conditions such as endometriosis, polycystic ovary syndrome (PCOS), and uterine fibroids have become increasingly common, leading to a surge in demand for effective and specialized treatments. Endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, affects a substantial portion of the female population, causing chronic pain and infertility. This debilitating condition significantly impacts women’s quality of life, driving the need for targeted therapies that can alleviate symptoms and address the underlying issues. Similarly, PCOS is a prevalent disorder characterized by hormonal imbalances and the presence of multiple ovarian cysts. It results in a range of symptoms, including irregular menstrual cycles, acne, weight gain, and metabolic disturbances. The high incidence of PCOS has intensified the demand for pharmaceutical interventions that can manage symptoms, regulate menstrual cycles, and mitigate associated health risks, such as insulin resistance and cardiovascular disease. According to a study conducted titled, “The prevalence of vulvovaginal symptoms in Japanese women of reproductive and perimenopausal ages: A cross-sectional study across generations”, the study sheds light on the prevalence of vulvovaginal issues among reproductive and perimenopausal women in Japan, as well as their hygiene practices. Approximately 80% of Japanese women surveyed reported experiencing some form of vaginal or vulvar health issue, a figure comparable to that found in a previous survey of women aged 18–44 in 11 European countries, Brazil, and Canada, although the earlier survey had a limited sample size for younger women. While bacterial vaginosis affects about 25% of reproductive-age women globally, this study indicates that a higher proportion of Japanese women experience various vulvovaginal problems, not limited to bacterial vaginosis. Notably, 77% of participants did not discuss their symptoms with anyone, suggesting a considerable number of undiagnosed cases of bacterial vaginosis in Japan. This study is the first to evaluate the prevalence of vulvovaginal issues specifically in Japanese women within these age groups.
Uterine fibroids, which are benign tumors of the uterus, affect a large segment of the female population. These fibroids can lead to severe symptoms, such as heavy menstrual bleeding, pelvic pain, and reproductive issues. The increased prevalence of uterine fibroids has spurred demand for effective treatments that can reduce symptoms, shrink fibroids, and offer relief without the need for invasive surgical procedures. The rising number of diagnosed cases of these gynecological conditions can be largely attributed to advancements in diagnostic techniques and greater awareness among both healthcare providers and patients. The development of sophisticated imaging technologies, such as transvaginal ultrasound and MRI, has significantly improved the ability to detect these disorders early. These technologies provide detailed images of the reproductive organs, allowing for more accurate diagnoses and timely interventions.
Expansion of Distribution Channels
The expansion of distribution channels is a pivotal driver of growth in the Japan gynecology drugs market. The development and diversification of distribution networks, including retail pharmacies, online pharmacies, and hospital pharmacies, have significantly enhanced the accessibility and availability of gynecology medications, thereby meeting the increasing demand for effective treatments.
Retail pharmacies have traditionally been a cornerstone of the drug distribution system, offering direct access to medications. They provide essential services such as personalized advice, patient counseling, and immediate availability of both prescription and over-the-counter (OTC) gynecology drugs. Retail pharmacies are strategically located in communities, making it convenient for patients to obtain their medications without having to travel long distances. The presence of knowledgeable pharmacists in these settings also allows for tailored guidance and support, which can be particularly beneficial for patients managing chronic or complex gynecological conditions. Online pharmacies, on the other hand, have emerged as a significant force in the distribution landscape, revolutionizing the way patients access medications. The convenience of online pharmacies, coupled with the ability to order drugs from the comfort of one's home, has contributed to their rapid growth. These platforms offer a wide array of products, including both prescription and OTC gynecology drugs, often with the added advantage of discreet packaging and home delivery. The rise of e-commerce and digital health solutions has further accelerated the adoption of online pharmacies, making it easier for patients to access necessary medications, especially those who may face barriers to visiting physical pharmacies.
Hospital pharmacies are integral to the Japan Gynecology Drugs Market, particularly for patients with severe or complex gynecological conditions. These pharmacies are equipped to handle specialized medications and provide a range of pharmaceutical services tailored to inpatient and outpatient care. Hospital pharmacies work closely with healthcare providers to ensure that patients receive the most appropriate therapies, manage drug interactions, and adjust dosages as needed. The role of hospital pharmacies extends beyond mere dispensing; they are vital in the comprehensive management of patient care, including the administration of medications and monitoring of treatment efficacy. The expansion of these distribution channels is driven by several factors The increasing prevalence of gynecological disorders and the growing demand for effective treatments necessitate broader access to medications. Technological advancements and digital innovations have enabled the growth of online pharmacies, making it easier for patients to obtain medications remotely. Evolving healthcare practices emphasize patient-centered care, which includes the convenience and personalized services offered by retail pharmacies and the specialized care provided by hospital pharmacies.
Growing Focus on Women's Wellness Programs
The growing focus on women's wellness programs is significantly influencing the Japan gynecology drugs market by promoting a holistic approach to women's health that emphasizes comprehensive care and preventive measures. These programs are designed to address a broad spectrum of women's health needs, extending beyond mere treatment to encompass preventive care, health education, and lifestyle counseling. By fostering a proactive approach to health management, these programs play a crucial role in identifying and addressing gynecological conditions early, which in turn drives demand for gynecology medications. Women's wellness programs typically include routine gynecological screenings, such as Pap smears, mammograms, and pelvic exams, which are essential for the early detection of conditions like cervical cancer, breast cancer, and various gynecological disorders. These screenings help in identifying health issues before they progress to more severe stages, thereby reducing the burden of advanced diseases and improving patient outcomes. By encouraging regular check-ups and preventive care, these programs help to catch conditions such as endometriosis, polycystic ovary syndrome (PCOS), and uterine fibroids early, which can be managed more effectively with timely medical intervention.
Health education is another critical component of women's wellness programs. These initiatives aim to educate women about the importance of regular health screenings, the benefits of a healthy lifestyle, and the management of gynecological conditions. By increasing awareness about the signs and symptoms of various gynecological disorders, these programs empower women to seek medical care when needed. This heightened awareness leads to increased utilization of gynecology drugs as more women become proactive about their health and pursue treatments for diagnosed conditions. Lifestyle counseling is also integral to wellness programs, as it addresses factors that can impact gynecological health, such as diet, exercise, and stress management. For example, women with PCOS or endometriosis may benefit from lifestyle modifications that can help manage symptoms and improve overall health. Wellness programs that include lifestyle counseling provide valuable support and guidance, contributing to better management of gynecological conditions and, consequently, a higher demand for relevant medications.
Rising Incidence of Infertility Issues
The rising incidence of infertility issues is a major driver of the Japan gynecology drugs market, reflecting a growing recognition of infertility as a significant health concern affecting both men and women. Infertility, which involves the inability to conceive after a year of regular, unprotected intercourse, is increasingly prevalent, influenced by a variety of factors including lifestyle changes, environmental conditions, and age-related declines in fertility. Lifestyle changes such as increased stress, sedentary habits, poor dietary choices, and late childbearing are contributing to the rise in infertility rates. Modern living often involves high-pressure careers and delayed family planning, both of which can negatively impact reproductive health. Environmental influences, including exposure to pollutants and chemicals, also play a role in decreasing fertility. Age-related fertility decline is a critical factor, as both men and women experience reduced reproductive capacity with advancing age, particularly after the mid-30s. In Japan, 18.2% of couples have sought or are currently seeking infertility testing or treatment, which equates to roughly 1 in 5.5 couples. In 2017, assisted reproductive technologies, such as in vitro fertilization and intra-cytoplasmic sperm injection, resulted in the birth of 56,617 babies, representing approximately 6.0% of the total 946,065 births in Japan. During the same year, about 450,000 fertility treatments were administered, positioning Japan among the leading countries globally in the use of such treatments. Over half (55%) of women undergoing advanced fertility treatments experience levels of depression that exceed mild severity.
The growing prevalence of infertility has heightened awareness and demand for effective fertility treatments. This shift is prompting pharmaceutical companies to invest significantly in developing and offering a range of specialized treatments. Key treatments include ovulation stimulants, fertility enhancers, and assisted reproductive technologies (ART). Ovulation stimulants, such as clomiphene citrate and letrozole, help regulate and induce ovulation in women with irregular or absent ovulation. Fertility enhancers, including medications like gonadotropins and human chorionic gonadotropin (hCG), support the development of healthy eggs and improve the chances of successful conception. ART, encompassing procedures such as in vitro fertilization (IVF) and intrauterine insemination (IUI), provides advanced solutions for couples facing severe infertility issues. The rise in awareness and focus on infertility issues is driving market growth by expanding the demand for these specialized gynecology drugs. Increased public and medical awareness about infertility and available treatment options encourages more individuals and couples to seek medical assistance and explore fertility solutions. This heightened awareness is supported by educational campaigns, advocacy groups, and media coverage, all of which contribute to a more informed patient base and a greater willingness to pursue fertility treatments.
Key Market Challenges
Regulatory Hurdles and Approval Delays
The Japan gynecology drugs market faces significant challenges related to regulatory hurdles and approval delays. Japan’s regulatory environment, governed by the Ministry of Health, Labor and Welfare (MHLW), requires rigorous testing and extensive documentation before a new gynecology drug can be approved for use. This process is essential to ensure the safety and efficacy of medications, but it can also be time-consuming and costly. Pharmaceutical companies must navigate a complex approval pathway that includes preclinical trials, clinical trials, and post-market surveillance. Each stage requires detailed submission of data, which must meet stringent regulatory standards. Delays in approval can be caused by several factors, including incomplete data submissions, the need for additional studies, or unforeseen regulatory requirements. Such delays not only increase the development costs for pharmaceutical companies but also affect the market availability of new treatments, impacting patients who may be in urgent need of novel therapies. Regulatory changes and updates can introduce uncertainties and further complicate the approval process. Companies must stay informed about evolving regulations and adapt their strategies accordingly, which requires dedicated resources and expertise. The intricate and often lengthy regulatory procedures present a substantial challenge to the timely introduction of new gynecology drugs in the Japan market.
High Costs of Drug Development
The high costs associated with drug development represent a significant challenge for the Japan gynecology drugs market. Developing new medications, especially those for specialized fields like gynecology, involves substantial financial investment. The process encompasses several stages, including discovery, preclinical testing, clinical trials, and regulatory approval. Each stage requires considerable funding for research, technology, materials, and human resources. Clinical trials alone, which are critical for proving a drug’s efficacy and safety, can be particularly expensive due to the need for large sample sizes, extensive monitoring, and long trial durations. The costs associated with maintaining compliance with stringent regulatory standards and conducting post-market surveillance add to the overall financial burden. For smaller pharmaceutical companies or startups, these high development costs can be a barrier to entry, limiting innovation and competition within the market. Established companies with more financial resources are better positioned to absorb these costs and bring new drugs to market, potentially creating disparities in the availability of new treatments. The high costs of drug development not only impact the pharmaceutical companies but also influence the pricing of medications, which can affect accessibility for patients and healthcare systems.
Key Market Trends
Advancements in Drug Development
Technological advancements in drug development are significantly propelling the Japan gynecology drugs market, introducing a host of innovations that enhance treatment efficacy and patient convenience. One major area of advancement is the development of novel hormonal therapies. Modern hormone replacement therapy (HRT) formulations now offer more precise dosing with reduced side effects compared to older versions. These innovations ensure better management of symptoms associated with menopause and other hormonal imbalances, providing patients with more comfortable and effective options for their conditions.
The shift towards non-hormonal treatments represents another pivotal advancement in the Japan Gynecology Drugs Market. For conditions such as menopause and endometriosis, non-hormonal alternatives are becoming increasingly prominent. These treatments cater to patients who either cannot tolerate hormonal therapies due to adverse effects or prefer not to use them for personal reasons. Non-hormonal options, such as selective serotonin reuptake inhibitors (SSRIs) for managing hot flashes or novel anti-inflammatory agents for endometriosis, offer effective symptom relief without the risks associated with hormonal therapies. This diversification in treatment options expands the market by accommodating a wider range of patient preferences and needs.
Improved drug delivery systems are also transforming the landscape of gynecological treatments. Innovations such as transdermal patches and intrauterine devices (IUDs) are enhancing both the efficacy and convenience of therapies. Transdermal patches, for example, provide a steady release of medication over an extended period, reducing the need for daily dosing and improving patient adherence. IUDs, on the other hand, offer long-term, localized delivery of hormonal or non-hormonal agents directly within the uterine cavity, ensuring targeted treatment for conditions like heavy menstrual bleeding or contraception. These advanced delivery methods not only enhance the effectiveness of treatments but also simplify the management of chronic conditions, leading to better patient outcomes.
Advancements in Diagnostic Technologies
Advancements in diagnostic technologies are playing a crucial role in the growth of the Japan gynecology drugs market by enabling earlier and more precise detection of gynecological disorders. Innovations in high-resolution imaging techniques, such as ultrasound, magnetic resonance imaging (MRI), and hysteroscopy, have revolutionized the ability to visualize the reproductive organs in greater detail. These technologies allow for the identification of various gynecological conditions at much earlier stages compared to traditional methods. For instance, advanced ultrasound technologies offer improved resolution and contrast, facilitating the early detection of abnormalities such as ovarian cysts, fibroids, and endometrial lesions. Similarly, MRI provides detailed images of soft tissues, enabling accurate assessment of complex conditions like endometriosis and tumors. Hysteroscopy, a minimally invasive procedure, allows for direct visualization of the uterine cavity, aiding in the diagnosis of intrauterine pathologies such as polyps or fibroids.
The ability to detect gynecological conditions at an early stage is critical for effective treatment and management. Early diagnosis often translates into more timely and less invasive interventions, improving patient outcomes and potentially reducing the need for more aggressive treatments later on. For example, the early detection of precancerous lesions or early-stage cancers allows for the implementation of targeted therapies and monitoring strategies that can significantly improve prognosis and reduce the overall burden of the disease. The development of molecular diagnostic tools and biomarkers has enhanced the precision of gynecological diagnoses. Molecular diagnostics involve analyzing biological markers in blood, tissues, or other bodily fluids to identify specific disease states or predispositions. For example, the identification of genetic markers associated with breast cancer or ovarian cancer can lead to more personalized treatment plans that are tailored to the individual’s genetic profile. Biomarkers can also be used to monitor disease progression or response to treatment, allowing for more adaptive and personalized therapeutic strategies.
Segmental Insights
Therapeutics Insights
Based on the Therapeutics, hormonal therapy is currently the dominant approach compared to non-hormonal therapy. Hormonal therapies are extensively used to manage a wide range of gynecological conditions, including menopausal symptoms, endometriosis, and polycystic ovary syndrome (PCOS). These therapies primarily involve the administration of hormones, such as estrogen and progesterone, to address hormonal imbalances and alleviate symptoms associated with these conditions.
Hormonal therapy is particularly prevalent in managing menopausal symptoms. For many women experiencing menopause, hormonal replacement therapy (HRT) provides significant relief from symptoms such as hot flashes, night sweats, and vaginal dryness. HRT helps to replace the estrogen that the body no longer produces in adequate amounts, thereby improving quality of life and reducing the risk of osteoporosis. This widespread application of hormonal therapy makes it a major component of the Japan Gynecology Drugs Market. In addition to menopause, hormonal therapy is also crucial in treating conditions like endometriosis, where the growth of endometrial tissue outside the uterus leads to severe pain and infertility. Hormonal treatments, such as birth control pills and progestins, help to regulate menstrual cycles and reduce the growth of endometrial tissue, thereby managing symptoms effectively. For women with PCOS, hormonal therapies are used to address irregular menstrual cycles and control excessive androgen levels, which can help manage symptoms like acne and excessive hair growth.
Indication Insights
Based on Indication, menopausal disorders currently dominate. Menopausal disorders, primarily managed through hormonal therapies and related medications, address a broad and significant segment of the market due to the large and growing population of women experiencing menopause and its associated symptoms. Menopause, which typically occurs in women between the ages of 45 and 55, marks the end of menstrual cycles and leads to a range of physiological and psychological symptoms due to the decline in estrogen and progesterone levels. Common symptoms include hot flashes, night sweats, vaginal dryness, mood swings, and insomnia. These symptoms can significantly impact a woman's quality of life, driving the demand for effective treatment options.
Hormonal Replacement Therapy (HRT) is the cornerstone of managing menopausal disorders. HRT aims to replenish the hormones that the body is no longer producing in adequate amounts, thereby alleviating the symptoms associated with menopause. The wide use of HRT, including estrogen-only and combined estrogen-progestin therapies, has established menopausal disorders as a key driver in the Japan Gynecology Drugs Market. The market for HRT is well-developed and continues to expand with ongoing advancements in formulation and delivery methods, such as transdermal patches and low-dose oral medications. In addition to HRT, non-hormonal therapies are also significant in managing menopausal disorders. These include selective serotonin reuptake inhibitors (SSRIs) for mood-related symptoms and vaginal moisturizers for dryness. The demand for non-hormonal treatments is growing, especially among women who are contraindicated for hormonal therapies due to health conditions or who prefer alternatives.
Regional Insights
Among the regions in Japan, Kanto dominates the Japan Gynecology Drugs Market. This region, which includes Tokyo, Yokohama, and other major cities, is the economic and population hub of the country, significantly influencing the healthcare sector, including gynecology. Kanto’s dominance is attributed to several factors. It is Japan’s most populous region, accounting for a substantial portion of the country's population. Tokyo, the capital city, is the most densely populated and economically vibrant city in Japan, with a large healthcare infrastructure that supports advanced medical treatments and research. The high population density in Kanto creates a significant demand for gynecological services and medications, ranging from hormonal therapies for menopausal disorders to treatments for gynecological cancers and reproductive health issues.
The presence of numerous leading hospitals, research institutions, and pharmaceutical companies in Kanto contributes to its market dominance. These institutions are at the forefront of medical innovation and clinical trials, leading to the development and introduction of new gynecology drugs. The concentration of medical and research facilities in Kanto provides residents with access to cutting-edge treatments and contributes to higher drug utilization rates in the region. Kanto's economic prosperity and high standard of living result in greater healthcare spending per capita. The region’s affluent population is more likely to invest in healthcare services and medications, including those for gynecological conditions. The availability of comprehensive healthcare services and a high level of health awareness among residents further drive the demand for gynecology drugs. The Kanto region also benefits from a robust distribution network, ensuring that gynecology medications are widely accessible. The region’s well-developed infrastructure facilitates efficient distribution and availability of pharmaceutical products, including specialized gynecology drugs. This accessibility is crucial for meeting the healthcare needs of a large and diverse population.
Key Market Players
• Novartis Pharma K.K.
• AbbVie GK
• Janssen Pharmaceuticals K.K.
• Asahi Kasei Pharma Corporation
• Sun Pharma Japan Limited
• Kyowa Pharmaceutical Industry Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Senju Pharmaceutical Co., Ltd.
• Taisho Pharmaceutical Co., Ltd.
Report Scope:
In this report, the Japan Gynecology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Japan Gynecology Drugs Market, By Therapeutics:
o Hormonal Therapy
o Non-Hormonal Therapy
• Japan Gynecology Drugs Market, By Indication:
o Gynecology Cancers
o Menopausal Disorder
o Polycystic Ovary Syndrome
o Contraception
o Others
• Japan Gynecology Drugs Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Japan Gynecology Drugs Market, By Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Japan Gynecology Drugs Market.
Available Customizations:
Japan Gynecology Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Japan Gynecology Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutics (Hormonal Therapy and Non-Hormonal Therapy)
5.2.2. By Indication (Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, and Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. Hokkaido Gynecology Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutics
6.2.2. By Indication
6.2.3. By Distribution Channel
7. Tohoku Gynecology Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapeutics
7.2.2. By Indication
7.2.3. By Distribution Channel
8. Kanto Gynecology Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapeutics
8.2.2. By Indication
8.2.3. By Distribution Channel
9. Chubu Gynecology Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutics
9.2.2. By Indication
9.2.3. By Distribution Channel
10. Kansai Gynecology Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutics
10.2.2. By Indication
10.2.3. By Distribution Channel
11. Chugoku Gynecology Drugs Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapeutics
11.2.2. By Indication
11.2.3. By Distribution Channel
12. Shikoku Gynecology Drugs Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Therapeutics
12.2.2. By Indication
12.2.3. By Distribution Channel
13. Kyushu Gynecology Drugs Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Therapeutics
13.2.2. By Indication
13.2.3. By Distribution Channel
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
15.1. Merger & Acquisition (If Any)
15.2. Product Launches (If Any)
15.3. Recent Developments
16. Japan Gynecology Drugs Market: SWOT Analysis
17. Porter’s Five Forces Analysis
17.1. Competition in the Industry
17.2. Potential of New Entrants
17.3. Power of Suppliers
17.4. Power of Customers
17.5. Threat of Substitute Products
18. Competitive Landscape
18.1. Novartis Pharma K.K.
18.1.1. Business Overview
18.1.2. Company Snapshot
18.1.3. Products & Services
18.1.4. Financials (As Reported)
18.1.5. Recent Developments
18.1.6. Key Personnel Details
18.1.7. SWOT Analysis
18.2. AbbVie GK
18.3. Janssen Pharmaceuticals K.K.
18.4. Asahi Kasei Pharma Corporation
18.5. Sun Pharma Japan Limited
18.6. Kyowa Pharmaceutical Industry Co., Ltd.
18.7. Santen Pharmaceutical Co., Ltd.
18.8. Otsuka Pharmaceutical Co., Ltd.
18.9. Senju Pharmaceutical Co., Ltd.
18.10. Taisho Pharmaceutical Co., Ltd.
19. Strategic Recommendations
20. About Us & Disclaimer